Loading
A phase 2 trial of Adagrasib in metastatic cancer, run by Mirati Therapeutics Inc., active and no longer recruiting.
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) is a phase 2 interventional study registered as NCT05853575 by Mirati Therapeutics Inc., with 200 participants planned, started 2024-02-01 and due to reach its primary completion in 2026-10-30. Interventions recorded: Adagrasib. Conditions listed: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Adagrasib, KRAS & RAS inhibitors, Bristol Myers Squibb.
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/